Breakthrough Care for Treatment-Resistant Depression in Atlanta & Decatur
The landmark NIH STAR*D trial demonstrated that after two unsuccessful oral antidepressant trials, the likelihood of achieving remission with a third standard pill drops to roughly 13.7%—while systemic side effects climb. At Attuned Psychiatry in Decatur, GA, Dr. Gideon Matzkin, MD, ABPN offers Metro Atlanta's most complete interventional TRD suite under one roof: BrainsWay Deep TMS™, BrainsWay Deep TMS™ (Accelerated & Customized Protocols), REMS-certified SPRAVATO® (esketamine), and Ketamine therapy.
Inside Our BrainsWay Deep TMS™ & SPRAVATO® Suites
✓ 82% Deep TMS Response Rate
BrainsWay H1-Coil Deep TMS achieves an 82% response rate and 65% remission rate after 30 sessions in real-world TRD clinical settings.
✓ 87.2% Accelerated Deep TMS Response
FDA-cleared Accelerated & Customized BrainsWay Deep TMS™ protocols delivers a 7-day median time to remission.
✓ Rapid NMDA Glutamate Relief
REMS-certified SPRAVATO® (esketamine) nasal spray targets synaptic neuroplasticity for TRD and acute depressive crises.
Comparing Interventional TRD Modalities at Attuned Psychiatry
Because we offer both electromagnetic neuromodulation and rapid NMDA/glutamate therapies in one clinic, Dr. Matzkin recommends what truly fits your biology—not a single-device sales pitch.
| Treatment Modality | Primary Mechanism | Clinical Efficacy | Driving & Daily Routine | Insurance Coverage |
|---|---|---|---|---|
| BrainsWay Deep TMS™ (H1-Coil) | Deep H-Coil electromagnetic stimulation of bilateral DLPFC (up to 3.2 cm depth) | 82% Response / 65% Remission | 20-min sessions; drive yourself immediately before & after | In-Network (Aetna, TRICARE East, BCBS, Cigna, UHC, Medicare) |
| BrainsWay Deep TMS™ (Accelerated & Customized Protocols) | Condensed intermittent theta-burst (iTBS) H-Coil stimulation (5 sessions/day for 5 acute days) | 87.2% Response / 78.7% Remission | 9-min sessions spaced ~50 mins apart; drive yourself daily | Case-by-case coverage & transparent accelerated packages |
| SPRAVATO® (Esketamine) Nasal Spray | NMDA receptor antagonist triggering rapid BDNF & synaptic neuroplasticity | ~69% Response / ~52% Remission | 2-hour monitored clinic suite; requires arranged ride home | In-Network (Aetna, TRICARE East, BCBS, Cigna, UHC, Medicare) + $10 Copay Card |
| 3rd+ Oral Antidepressant Switch (STAR*D) | Systemic monoamine reuptake (SSRI / SNRI / augmentation) | ~13.7% Remission (Step 3) | Daily oral pill; risk of systemic weight, sexual, or sleep side effects | Standard pharmacy benefit |
Frequently Asked Questions
Clinically and for most insurance plans (including Aetna, TRICARE East, BCBS, Cigna, Optum/UHC, and Medicare), Treatment-Resistant Depression is defined as Major Depressive Disorder that has not responded adequately to at least two trials of oral antidepressant medications of adequate dose and duration during the current depressive episode.
Both are FDA-approved, insurance-covered breakthroughs with distinct strengths. BrainsWay Deep TMS is completely non-systemic, drug-free, takes 20 minutes per session, and allows you to drive yourself immediately afterward. SPRAVATO works rapidly via the glutamate/NMDA pathway (often within days to weeks) and requires a 2-hour monitored stay and a ride home. During your comprehensive evaluation, Dr. Matzkin helps you compare both based on your medical history, schedule, and insurance benefits.
Yes. For patients with refractory symptoms, sequential or combined Deep TMS and SPRAVATO protocols can target both cortical network excitability and synaptic glutamate neuroplasticity under Dr. Matzkin's supervision.
Ready to See if BrainsWay Deep TMS™ Is Right for You?
Whether you are seeking a comprehensive psychiatric evaluation, exploring BrainsWay Deep TMS™ or SPRAVATO®, or looking for a collaborative second opinion, our Decatur team is here for you.
Clinic Location & Direct Contact
Request Your Consultation
Complete the brief form below and our Decatur intake coordinator will reach out within 1 business day.